U.S. markets closed

Nkarta, Inc. (NKTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.00-0.89 (-3.58%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.89
Open24.85
Bid23.00 x 2200
Ask25.00 x 900
Day's Range23.60 - 25.40
52 Week Range23.60 - 58.69
Volume122,484
Avg. Volume300,109
Market Cap780.66M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Barrons.com

    Virtusa, Nkarta See Activist ActionsÁ

    New Mountain Vantage Advisers disclosed an interest of 2,979,665 shares of enterprise IT-services firm Virtusa. New Enterprise Associates revealed an initial position in Nkarta, an oncology biotech firm, of 2,902,115 shares.

  • MarketWatch

    Nkarta raises nearly $290 million in IPO

    Nkarta Inc. said late Tuesday it raised $289.8 million in its recent public offering after underwriters exercised all their options for shares to cover overallotments. On Friday, the biotech company priced 16.1 million shares at $18 and offered underwriters options for an additional 2.1 million, but on the first day of trading, shares rocketed to a high of $58.69. In the meantime, shares have settled a bit, shedding 20% on Monday, and closing down 6.4% at $36.05 on Tuesday, for market cap of $1.1 billion.

  • GlobeNewswire

    Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif., July 14, 2020 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies.